TransMedics Group (TMDX) Misses Q3 EPS by 11c

TransMedics Group (NASDAQ: TMDX) reported Q3 EPS of ($0.47), $0.11 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $6.35 million.

GUIDANCE:

TransMedics Group sees FY2021 revenue of $27.6-28.6 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• KeyBanc Upgrades Nucor (NUE) to Overweight